LIFE-B:CA:TSX-Evolve Global Healthcare Enhanced Yield Fund UnHedged Units (CAD)

ETF | Others |

Last Closing

CAD 24.44

Change

0.00 (0.00)%

Market Cap

N/A

Volume

100.00

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-12 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XEF-U:CA iShares Core MSCI EAFE IMI Ind..

-0.25 (-0.96%)

CAD 6.19B
XEQT:CA iShares Core Equity Portfolio

-0.14 (-0.42%)

CAD 6.03B
CASH:CA GLOBAL X HIGH INTEREST SAVINGS..

+0.01 (+0.01%)

CAD 5.57B
PHYS-U:CA Sprott Physical Gold Trust

-0.18 (-0.87%)

CAD 4.76B
XUS-U:CA iShares Core S&P 500 Index ETF

N/A

CAD 4.54B
HXT-U:CA Global X S&P/TSX 60 Index ETF

-0.02 (-0.04%)

CAD 3.92B
CEF-U:CA Sprott Physical Gold and Silve..

-0.55 (-2.20%)

CAD 3.78B
PSLV-U:CA Sprott Physical Silver Trust

-0.24 (-2.36%)

CAD 3.29B
ZMMK:CA BMO Money Market Fund ETF Seri..

+0.01 (+0.02%)

CAD 3.24B
NSCB:CA NBI Sustainable Canadian Bond ..

+0.11 (+0.49%)

CAD 2.78B

ETFs Containing LIFE-B:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 1.16% 84% B 72% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.16% 84% B 72% C
Trailing 12 Months  
Capital Gain -2.20% 8% B- 18% F
Dividend Return 7.04% 89% A- 88% B+
Total Return 4.84% 22% F 26% F
Trailing 5 Years  
Capital Gain 5.48% 40% F 45% F
Dividend Return 36.71% 92% A 91% A-
Total Return 42.19% 63% D 57% F
Average Annual (5 Year Horizon)  
Capital Gain 2.27% 45% F 41% F
Dividend Return 2.79% 46% F 36% F
Total Return 0.52% 76% C+ 31% F
Risk Return Profile  
Volatility (Standard Deviation) 5.92% 76% C+ 89% A-
Risk Adjusted Return 47.15% 60% D- 59% D-
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.